Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2640-2649

  Han, Min ^a,b   Vakili, Mohammad Reza ^a   Soleymani Abyaneh, Hoda ^a   Molavi, Ommoleila ^a,c   Lai, Raymond ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ZHEJIANG UNIVERSITY   (China)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

doxorubicin (DOX); drug resistance; MDA MB 435; mitochondrion; triphenylphosphonium (TPP)

Indexed keywords

CASPASE 3; DOXORUBICIN; NANOCARRIER; TRIPHENYLPHOSPHINE; ANTINEOPLASTIC ANTIBIOTIC; ORGANOPHOSPHORUS COMPOUND;

APOPTOSIS; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MITOCHONDRION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DRUG DESIGN; DRUG EFFECTS; IC50; INFRARED SPECTROPHOTOMETRY; METABOLISM; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; TIME; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DOXORUBICIN; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MITOCHONDRIA; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; SPECTROPHOTOMETRY, INFRARED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TIME FACTORS;

EID: 84905492641     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500038g     Document Type: Article

References (27)

1. Baguley, B. C. Multiple drug resistance mechanisms in cancer Mol. Biotechnol. 2010, 46 (3) 308-16
2. Duvvuri, M.; Krise, J. P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review Front. Biosci. 2005, 10, 1499-509
3. Chamberlain, G. R.; Tulumello, D. V.; Kelley, S. O. Targeted Delivery of Doxorubicin to Mitochondria ACS Chem. Biol. 2013, 8 (7) 1389-95
4. Green, D. R.; Reed, J. C. Mitochondria and apoptosis Science 1998, 281 (5381) 1309-12
5. Pathania, D.; Millard, M.; Neamati, N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism Adv. Drug Delivery Rev. 2009, 61 (14) 1250-75
6. DSouza, G. G.; Wagle, M. A.; Saxena, V.; Shah, A. Approaches for targeting mitochondria in cancer therapy Biochim. Biophys. Acta 2011, 1807 (6) 689-96
7. Smith, R. A.; Hartley, R. C.; Murphy, M. P. Mitochondria-targeted small molecule therapeutics and probes Antioxid Redox Signal 2011, 15 (12) 3021-38
8. Fulda, S.; Kroemer, G. Mitochondria as therapeutic targets for the treatment of malignant disease Antioxid. Redox Signaling 2011, 15 (12) 2937-49
9. Huigsloot, M.; Tijdens, I. B.; Mudler, G. J.; van de Water, B. Differential Regulation of Doxorubicin-induced Mitochondrial Dysfunction and Apoptosis by Bcl-2 in Mammary Adenocarcinoma (MTLn3) Cells J. Biol. Chem. 2002, 277, 35869-79
10. Singh, K. K.; Russell, J.; Sigala, B.; Zhang, Y.; Williams, J.; Keshav, F. K. Mitochondrial DNA determines the cellular response to cancer therapeutic agents Oncogene 1999, 18 (48) 6641-6
11. Malhi, S. S.; Budhiraja, A.; Arora, S.; Chaudhari, K. R.; Nepali, K.; Kumar, R.; Sohi, H.; Murthy, R. S. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes Int. J. Pharm. 2012, 432 (1-2) 63-74
12. Vasquez-Vivar, J.; Martasek, P.; Hogg, N.; Masters, B. S.; Pritchard, K. A., Jr.; Kalyanaraman, B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin Biochemistry 1997, 36 (38) 11293-7
13. Murphy, M. P. Targeting lipophilic cations to mitochondria Biochim. Biophys. Acta 2008, 1777 (7-8) 1028-31
14. Smith, R. A.; Porteous, C. M.; Gane, A. M.; Murphy, M. P. Delivery of bioactive molecules to mitochondria in vivo Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (9) 5407-12
15. Durazo, S. A.; Kompella, U. B. Functionalized nanosystems for targeted mitochondrial delivery Mitochondrion 2012, 12 (2) 190-201
16. Malhi, S. S.; Murthy, R. S. Delivery to mitochondria: a narrower approach for broader therapeutics Expert Opin. Drug Delivery 2012, 9 (8) 909-35
17. Falamarzian, A.; Aliabadi, H. M.; Molavi, O.; Seubert, J. M.; Lai, R.; Uludaǧ, H.; Lavasanifar, A. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy J. Biomed Mater. Res., Part A 2013, 10.1002/jbma.34992
18. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy Nat. Rev. Drug Discovery 2010, 9, 447-464
19. Xiong, X. B.; Ma, Z.; Lai, R.; Lavasanifar, A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin Biomaterials 2010, 31 (4) 757-68
20. Chamberlain, G. R.; Tulumello, D. V.; Kelley, S. O. Targeted Delivery of Doxorubicin to Mitochondria ACS Chem. Biol. 2013, 8 (7) 1389-95
21. Zhang, Y.; Li, R. J.; Ying, X.; Tian, W.; Yao, H. J.; Men, Y.; Yu, Y.; Zhang, L.; Ju, R. J.; Wang, X. X.; Zhou, J.; Chen, J. X.; Li, N.; Lu, W. L. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer Mol. Pharmaceutics 2011, 8 (1) 162-75
22. Riganti, C1; Rolando, B.; Kopecka, J.; Campia, I.; Chegaev, K.; Lazzarato, L.; Federico, A.; Fruttero, R.; Ghigo, D. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance Mol. Pharmaceutics 2013, 10 (1) 161-74
23. Aliabadi, H. M.; Mahdipoor, P.; Uludaǧ, H. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells Cancer Gene Ther. 2013, 20 (3) 169-77
24. Theodossiou, T. A.; Sideratou, Z.; Katsarou, M. E.; Tsiourvas, D. Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity Pharm. Res. 2013, 30 (11) 2832-42
25. Marrache, S.; Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (40) 16288-93
26. Biswas, S.; Dodwadkar, N. S.; Deshpande, P. P.; Torchilin, V. P. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium- PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo J. Controlled Release 2012, 159 (3) 393-402
27. Zhou, J.; Zhao, W. Y.; Ma, X.; Ju, R. J.; Li, X. Y.; Li, N.; Sun, M. G.; Shi, J. F.; Zhang, C. X.; Lu, W. L. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer Biomaterials 2013, 34 (14) 3626-38